Europe's Off-Patent Industry Seeks Action On Shortages
Medicines For Europe Asks New European Commission For ‘Policy Response’
Medicines For Europe has called on EU leaders to take action on the issue of medicine shortages, urging the new European Commission to prioritize prevention measures in its first 100 days.
You may also be interested in...
Christoph Stoller, Teva’s general manager for Germany and Austria, has just been announced as president of European off-patent industry association Medicines for Europe with a two-year mandate. In an exclusive interview, he sets out the organization’s immediate priorities.
Strides has acquired 18 ANDAs from Pharmaceutics International, as well as exclusive marketing rights to a levothyroxine sodium candidate. Through this agreement, the Indian company plans to expand its niche offerings.
Teva UK’s director of secondary care, Andrew Ellis, who has been a member of the British Biosimilars Association’s steering group, has now been appointed as its new chair.